NPM1 and acute myeloid leukemia: In 2011, the AMLSG initiated the randomized AMLSG 15–10 trial in older patients with newly diagnosed AML with NPM1 mutation not fit for intensive chemotherapy evaluating ATRA in combination with low-dose cytarabine plus etoposide.